What is a better marker for hepatocellular injury?

ALT is the better marker for hepatocellular injury

ALT (alanine aminotransferase) remains the gold standard biomarker for detecting hepatocellular injury, with GLDH (glutamate dehydrogenase) emerging as a superior alternative in specific clinical contexts where liver-specific injury needs to be distinguished from muscle damage 1.

Primary Markers for Hepatocellular Injury

ALT as the Standard

ALT is the established primary marker for hepatocellular injury and should be monitored routinely 1. The key tests for detecting hepatocellular injury include:

• ALT and AST (aminotransferases) - characterize hepatocellular injury through aminotransferase elevations
• Total bilirubin (TBIL) - may accompany ALT/AST elevations
• ALP - should remain minimally elevated in pure hepatocellular injury (significant ALP elevation suggests cholestatic pattern instead)

GLDH as the Liver-Specific Alternative

GLDH demonstrates superior tissue specificity compared to ALT and should be used when muscle injury confounds the diagnosis 2, 3, 4. The evidence supporting GLDH includes:

• Pooled sensitivity of 87% and specificity of 86% for drug-induced liver injury 2
• Positive likelihood ratio of 6.30, meaning GLDH elevation substantially increases the probability of true hepatocellular injury 2
• Remains normal in muscle diseases while ALT is elevated 20-fold in conditions like Duchenne muscular dystrophy 3
• Correlates more closely with gold standard ALT than microRNA-122 4

Clinical Algorithm for Marker Selection

Use ALT as the first-line marker in all patients 1. However, switch to GLDH when:

1. Muscle disease is present (muscular dystrophy, rhabdomyolysis, chronic muscle disorders) 3
2. Elevated creatine kinase suggests concurrent muscle injury 3
3. Need to distinguish hepatocellular from muscle injury in critically ill patients 3

Important Caveats

Limitations of ALT

• Lacks liver specificity - can be elevated in both hepatic and non-hepatic (muscle) injury 2, 3
• In patients with Duchenne muscular dystrophy, serum ALT was increased 20-fold despite no liver injury, while GLDH remained normal 3
• In rhabdomyolysis, ALT, AST, and CK all elevated significantly, but GLDH stayed normal until actual hypoxia-induced liver injury occurred 3

GLDH Advantages

• Mitochondrial enzyme with hepatocyte enrichment provides tissue-specific information 1
• Currently undergoing regulatory evaluation as a liver injury biomarker 1
• Can indicate hepatic mitochondrial injury specifically 1

Monitoring Thresholds

For clinical trial exclusion criteria (which reflect severity thresholds):

• ALT >5× ULN with liver metastases/primary cancer warrants exclusion 1
• ALT >3× ULN without metastases warrants exclusion 1
• Two pre-treatment ALT values are best practice to exclude rapidly rising ALT from alternative causes 1

Complementary Markers

While ALT/GLDH are primary markers, AST should be measured concurrently to characterize the injury pattern 1. The AST/ALT ratio provides additional diagnostic information about chronicity and severity.

For prognostic assessment (not diagnosis), cytokeratin 18, osteopontin, and macrophage colony-stimulating factor receptor show promise for predicting liver-related death or transplantation 4, but these are not diagnostic markers for hepatocellular injury itself.